<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Mesothelin is overexpressed in several <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and is purportedly a specific marker of <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this pilot study, we investigated whether tissue and serum mesothelin are potential markers of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) and in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (EAC) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Mesothelin expression was retrospectively evaluated in <z:mpath ids='MPATH_458'>normal</z:mpath>, BE, and EAC tissue from surgically resected esophageal specimens (n = 125) </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, soluble mesothelin-related <z:chebi fb="7" ids="16670">peptide</z:chebi> (SMRP) levels were measured in serum </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:mpath ids='MPATH_458'>Normal</z:mpath> esophageal mucosa did not express mesothelin </plain></SENT>
<SENT sid="5" pm="."><plain>BE tissue with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> specifically expressed mesothelin, whereas BE tissue with low-grade or without <z:mpath ids='MPATH_589'>dysplasia</z:mpath> did not </plain></SENT>
<SENT sid="6" pm="."><plain>Fifty-seven (46%) EAC <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were positive for mesothelin </plain></SENT>
<SENT sid="7" pm="."><plain>EAC <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with BE expressed mesothelin more often than those without BE (58% vs. 35%, P = 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>SMRP levels were elevated in 70% of EAC patients (mean = 0.89 nmol/L; range: 0.03-3.77 nmol/L), but not in patients with <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> and/or BE </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Mesothelin is commonly expressed in BE-associated EAC </plain></SENT>
<SENT sid="10" pm="."><plain>On the basis of this pilot study, a prospective study is under way to evaluate tissue and serum mesothelin which are potential markers of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> in BE and in EAC (NCT01393483) </plain></SENT>
<SENT sid="11" pm="."><plain>IMPACT: Current surveillance methods in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> are invasive and neither cost-effective nor sensitive </plain></SENT>
<SENT sid="12" pm="."><plain>This pilot study suggests that serum mesothelin is a marker of <z:e sem="disease" ids="C0007621" disease_type="Neoplastic Process" abbrv="">neoplastic transformation</z:e> in BE and may provide a noninvasive method to improve identification of <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> </plain></SENT>
</text></document>